Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
351 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (2)

Medical Condition

  • Show all (182)
  • Autoimmune Disorders (3)
  • Blood Disorders (8)
  • Cancer (111)
    • Bladder Cancer (1)
    • Brain Cancer (2)
    • Breast Cancer (2)
    • Gastrointestinal (3)
    • (-) Gynecologic Cancer (3)
    • Head and Neck Cancer (2)
    • Kidney Cancer (3)
    • Leukemia (9)
    • Liver Cancer (1)
    • Lung Cancer (14)
    • Lymphoma (8)
    • Multiple Myeloma (6)
    • Pancreatic Cancer (1)
    • Prostate Cancer (9)
    • Sarcoma (4)
    • Skin Cancer (5)
    • Solid Tumors (7)
  • Diabetes (1)
  • Healthy Volunteers (3)
  • Heart Disease (2)
  • Infectious Disease (3)
  • Neurological Disorders (16)
  • Nutrition (1)
  • Obstetrics & Gynecology (1)
  • Pediatrics (15)
  • Psychiatric Disorders (1)
  • Transplant (16)
  • Urology (1)
Displaying 1 - 3 of 3

Study of TransCon IL-2 / vs. TransCon TLR7/8 Agonist in Patients with Gynecologic Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself or in combination with pembrolizumab, SOC chemotherapy, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of…
Read More

Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-…
Read More

Study of XmAb20717 in Patients with Gynecological Cancer (Cervical, Ovarian, or Endometrial)

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this study is to assess whether an investigational drug, called XmAb20717, has any effects on your cancer, and to determine if it is safe and well tolerated. XmAb20717 is a type of drug that can attach to 2 different proteins, call a bispecific antibody. These antibodies are designed to attach to a T-cell, a…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science